oricar-017
oricell therapeutics
[]
 100% overall response rate and 100% minimal residual disease negative rate, along with favorable safety support oricar-017 to be a competitive therapy for rrmm, investigators reported at #asco22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.